SMT Engineering issues AGM corrigendum clarifying preferential issue details
- SMT Engineering issued an AGM corrigendum on September 21, 2026, correcting errors in Item 5 of the notice.
- The amendment clarifies the total number of warrants as 1,42,858.
- Proceeds of ₹4,00,00,240 will fund a manufacturing unit at Chemerix Life Sciences Private Limited.
- ₹10,00,000 of the issue proceeds are allocated for general corporate purposes.

*this image is generated using AI for illustrative purposes only.
SMT Engineering issued a corrigendum to its Annual General Meeting (AGM) notice on September 21, 2026, addressing inadvertent errors in Item 5 concerning a proposed preferential issue. The company scheduled the AGM for September 30, 2026, to be conducted via video conferencing or other audio-visual means.
The correction modifies the explanatory statement related to the preferential allotment. Specifically, the company clarified the total number of warrants associated with the issue. The revised figure states the total number of warrants as 1,42,858.
Utilization of Proceeds
The corrigendum also updates the description of how the funds from the preferential issue will be deployed. The company stated that the proposed funds will be utilized for investment in Chemerix Life Sciences Private Limited, a step-down wholly owned subsidiary. The capital expenditure aims to set up a manufacturing unit, with additional proceeds allocated for general corporate purposes.
The detailed breakdown of the estimated amount to be utilized is as follows:
| Purpose | Estimated Amount (₹) | Timeline |
|---|---|---|
| Investment in Chemerix Life Sciences for manufacturing setup | 3,90,00,240 | Within 12 months |
| General Corporate Purposes | 10,00,000 | Within 12 months |
| Total | 4,00,00,240 |
The general corporate purposes component, capped at ₹10,00,000, will address ongoing exigencies, contingencies, and expenses as decided by the Board. The company noted that these figures consider 100% conversion of warrants into equity shares within the stipulated time.
What the Numbers Show
The preferential issue structure indicates a heavy concentration of capital deployment toward a specific strategic vertical. With ₹3,90,00,240 allocated to Chemerix Life Sciences against a total raise of ₹4,00,00,240, approximately 97.5% of the proceeds are earmarked for this single subsidiary’s manufacturing setup. This suggests the company is leveraging equity financing primarily to fund expansion in the life sciences segment rather than for broad-based working capital needs.
Historical Stock Returns for SMT Engineering
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -5.00% | -8.43% | -21.51% | -29.81% | +504.21% | 0.0% |
How will the heavy concentration of 97.5% of proceeds into Chemerix Life Sciences impact SMT Engineering's overall risk profile and diversification strategy?
What is the expected timeline for Chemerix Life Sciences to achieve operational profitability after the manufacturing unit setup is completed within the next 12 months?
Given that the warrant count was corrected in the AGM notice, are there any potential regulatory implications or shareholder concerns regarding the initial disclosure errors?


































